The Access to Birth Control Act would amend the Public Health Service Act to impose federal duties on pharmacies that dispense FDA-approved contraception and related medications. If a pharmacy stocks the requested product, it would have to provide it without delay. If the product is not in stock, the pharmacy would have to promptly tell the customer and either transfer the prescription to another pharmacy that has it or order it through expedited procedures if the customer prefers. The bill also requires pharmacies to avoid intimidation, harassment, obstruction, misinformation, breaches of confidentiality, and refusal to return valid prescriptions in connection with contraception requests.
The bill defines contraception broadly to include FDA-approved drugs and devices used to prevent pregnancy, and it covers medications a medical professional determines are necessary before or alongside contraception. It applies to pharmacies engaged in retail prescription sales and includes enforcement mechanisms such as civil penalties of up to $1,000 per day, capped at $100,000 per proceeding, and a private right of action for aggrieved persons seeking damages, injunctive relief, and attorney’s fees. The bill would take effect 31 days after enactment and expressly preserves stronger state protections while limiting certain religious-freedom defenses under RFRA for claims brought under the new section.
The bill’s stated purpose is to reduce barriers to birth control access and respond to reports of pharmacists refusing to fill contraceptive prescriptions or provide emergency contraception, especially after the Dobbs decision. Its findings emphasize contraception as basic health care, reproductive autonomy, and a tool for reducing unintended pregnancy, while also noting disparities tied to cost, geography, immigration status, language access, and discrimination. The measure would therefore create a federal floor for pharmacy conduct related to contraception access, while allowing states and licensing boards to maintain or adopt stronger customer protections.
Because the bill was only introduced and referred to the House Committee on Energy and Commerce, there is no recorded committee debate or vote history in the provided materials. The overall sentiment reflected in the bill text is strongly supportive of expanded contraceptive access and skeptical of pharmacy refusals based on personal or religious objections. The findings frame the issue as one of public health, civil rights, and reproductive autonomy, and the bill is designed to prevent delays or denials in access to birth control and related medications.
The main point of contention likely concerns the balance between patient access and pharmacist or pharmacy objections, including religious liberty, conscience claims, and professional discretion. The bill attempts to address those issues by allowing refusals for lack of a valid prescription, inability to pay, or professional clinical judgment, while also stating that RFRA cannot be used as a defense to claims under the new section. Another possible area of dispute is federal preemption and the creation of a private right of action, which could expose pharmacies to litigation and compliance costs.
The bill would add a new section to the Public Health Service Act establishing federal standards for pharmacies that handle FDA-approved contraception and related medications. It would require prompt dispensing, referral, transfer, or ordering procedures, prohibit certain obstructive or deceptive conduct by pharmacy employees, and create enforcement through civil penalties and private lawsuits. The bill would not preempt stronger state laws or professional obligations, but it would set a nationwide baseline for pharmacy access to contraception and related medications.
The bill is presented in strongly pro-access terms, with findings emphasizing reproductive autonomy, public health, and the need to remove barriers to birth control. The text reflects concern about post-Dobbs refusals by pharmacies and frames the legislation as a response to discrimination, stigma, and delays in care. No votes or committee remarks were provided, so the available record shows support from the sponsors and cosponsors but no formal opposition in the supplied materials.
The likely controversy centers on whether federal law should require pharmacies to dispense or facilitate access to contraception despite employee or institutional objections. The bill narrows but does not eliminate refusal rights by allowing denials for legal, payment, or clinical-judgment reasons, while also limiting RFRA-based defenses and creating a private cause of action. Additional tension may arise over the bill’s enforcement provisions, including monetary penalties, litigation exposure, and the extent of federal involvement in pharmacy practice and state licensing regimes.